3D Prostate Mapping

3d prostate

When testing to see if a patient has prostate cancer, the standard is performing a TRUS-GB (Trans-rectal Ultrasound Guided Biopsy). A TRUS biopsy consists of the insertion of an ultrasound probe approximately the size of an adult man’s thumb into your rectum. The ultrasound probe allows the doctor to inspect the prostate visually. It produces a gray pattern image which you may have seen in your doctor’s office. It is the same type of picture that is used to look at kidneys, liver, and at unborn babies in the obstetrician’s office. The doctor also can assess the prostate for abnormal areas, and sometimes measure the prostate and more accurately determine its size. Further, the ultrasound image allows the doctor to more accurately obtain 6 to12 needle core samples from the prostate to exclude evaluate for the possibility of prostate cancer being present.

The 3D Mapping Biopsy is different than the traditional TRUS biopsy in a number of ways. Firstly, it is carried out through the skin of the perineum (the area behind the scrotum and in front of the rectum) so the procedure is sterile and a larger number of prostate biopsy samples can safely be taken. Secondly, the prostate biopsy is biopsied performed atevery 5 millimeters intervals throughout it's whole volume. The number of core samples taken is therefore dependent on the size of a patient's prostate as opposed to an arbitrary number as in traditional TRUS biopsy. With 3D mapping tThe prostate biopsies are guided using a brachytherapy grid (similar to playing battleship) and the specimens are sent labeled as to it's exact location. If a biopsy therefore comes back positive, the cancer's exact location in the prostate is now known so it can later be targeted for treatment. Lastly, the procedure is always generally carried out under heavy sedation or general anesthesia.

The results we have obtained using this prostate biopsy method have changed our thinking about the staging of prostate cancer. We have found that more than 50% of the patients that who were thought to have only one sided cancer by traditional TRUS biopsy actually have cancer on both sides of the gland, and therefore have a larger volume cancer than initially thought. In addition, about 25% of the patients biopsied turn out to have an increase in their Gleason score after a 3D-PMB. Many of the patient's that we see that who are considering "watchful waitingactive surveillance" and then find out through 3D mapping biopsy that in actuality they are NOT good candidates for that management strategy.

For further information please call 407-584-7771



Get Help Today

We Accept:

visa logo  

The Outer Limit Studios: Orlando Website Design